IRRAS AB publishes Year End Report for the period January to December 2022
Commercial partnership underway to wrap up meaningful year of growth “Q4 2022 marked the conclusion of a transformational year for IRRAS, and, as we begin the new year, we have created new opportunities that will accelerate our growth toward achieving leadership in the world of neurocritical care.” “The 4th quarter also marked the start of an extremely exciting next phase for the launch of IRRAflow, our lead product, with the announcement of our commercial partnership with Medtronic, the world’s largest medical device company.” Will Martin, CEO of IRRASFourth quarter, October –